Desvenlafaxine Succinate hydrate | CAS#386750-22-7 | venlafaxine metabolite | SERT inhibitor | NET inhibitor

MedKoo Cat#: 540104 | Name: Desvenlafaxine Succinate hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Desvenlafaxine Succinate is a venlafaxine metabolite and inhibitor of SERT and NET used to treat depression. It also alters rates of gastric emptying and decreases symptoms of menopausal hot flashes.

Chemical Structure

Desvenlafaxine Succinate hydrate

CAS#386750-22-7 (succinate hydrate)

Theoretical Analysis

MedKoo Cat#: 540104

Name: Desvenlafaxine Succinate hydrate

CAS#: 386750-22-7 (succinate hydrate)

Chemical Formula: C20H33NO7

Exact Mass: 0.0000

Molecular Weight: 399.23

Elemental Analysis: C, 60.13; H, 8.33; N, 3.51; O, 28.03

Price and Availability

Size	Price	Availability
500mg	USD 450.00	2 Weeks
1g	USD 750.00	2 Weeks
2g	USD 1,350.00	2 Weeks
5g	USD 2,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

93413-62-8 (free base) 448904-47-0 (succinate) 386750-22-7 (succinate hydrate) 300827-87-6 (HCl) 93414-04-1 (fumarate) 1147940-37-1 (benzoate)

Synonym

Pristiq; Desvenlafaxine succinate monohydrate; Desvenlafaxine succinate hydrate; Desvenlafaxinesuccinatemonohydrate; DVS 233; DVS233; DVS-233; WY 45233; WY45233; WY-45233;

IUPAC/Chemical Name

4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol succinate hydrate

InChi Key

PWPDEXVGKDEKTE-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H25NO2.C4H6O4.H2O/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8;/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H2,(H,5,6)(H,7,8);1H2

SMILES Code

O=C(O)CCC(O)=O.OC1=CC=C(C(C2(O)CCCCC2)CN(C)C)C=C1.[H]O[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Desvenlafaxine is an active metabolite of the selective norepinephrine and serotonin reuptake inhibitor (SNRI) venlafaxine.

In vitro activity:

The purpose of this study was to characterize a new chemical entity, desvenlafaxine succinate (DVS). Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively. DVS showed weak binding affinity (62% inhibition at 100 microM) at the human dopamine (DA) transporter. Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively. DVS (10 microM), examined at a large number of nontransporter targets, showed no significant activity. In conclusion, DVS is a new 5-HT and NE reuptake inhibitor in vitro that demonstrates good brain-to-plasma ratios, suggesting utility in a variety of central nervous system-related disorders. Reference: J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. https://pubmed.ncbi.nlm.nih.gov/16675639/

In vivo activity:

Desvenlafaxine (DVS) was orally administrated to UCMS mice at the dose of 10 mg/kg/day 1 week before they went through a 7week stress procedure and lasted for over 8 weeks before the mice were killed. No significant changes were found for protein markers of neurons and astrocytes in UCMS mice. However, myelin and oligodendrocyte-related proteins were significantly reduced in UCMS mice. DVS prevented the stress-induced injury to white matter and the decrease of phosphorylated 5'-AMP-activated protein kinase and 3-hydroxy-3-methyl-glutaryl-CoA reductase protein expression. DVS increased open arm entries in an elevated plus-maze test, sucrose consumption in the sucrose preference test and decreased immobility in tail suspension and forced swimming tests. These findings suggest that stress induces depression-like behaviors and white matter deficits in UCMS mice. DVS may ameliorate the oligodendrocyte dysfunction by affecting cholesterol synthesis, alleviating the depression-like phenotypes in these mice Reference: J Neurochem. 2014 Oct;131(2):229-38. https://pubmed.ncbi.nlm.nih.gov/24934403/

	Solvent	mg/mL	mM
Solubility
	DMSO	3.0	7.51

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 399.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Asokan A, Ball AR, Laird CD, Hermer L, Ormerod BK. Desvenlafaxine may accelerate neuronal maturation in the dentate gyri of adult male rats. PLoS One. 2014 Jun 4;9(6):e98530. doi: 10.1371/journal.pone.0098530. PMID: 24896246; PMCID: PMC4045676. 2. Wang J, Qiao J, Zhang Y, Wang H, Zhu S, Zhang H, Hartle K, Guo H, Guo W, He J, Kong J, Huang Q, Li XM. Desvenlafaxine prevents white matter injury and improves the decreased phosphorylation of the rate-limiting enzyme of cholesterol synthesis in a chronic mouse model of depression. J Neurochem. 2014 Oct;131(2):229-38. doi: 10.1111/jnc.12792. Epub 2014 Jul 8. PMID: 24934403. 3. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. doi: 10.1124/jpet.106.103382. Epub 2006 May 4. PMID: 16675639

In vitro protocol:

1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. doi: 10.1124/jpet.106.103382. Epub 2006 May 4. PMID: 16675639.

In vivo protocol:

1: Tella SH, Gallagher JC. Efficacy of desvenlafaxine succinate for menopausal hot flashes. Expert Opin Pharmacother. 2014 Nov;15(16):2407-18. doi: 10.1517/14656566.2014.964641. Epub 2014 Sep 25. Review. PubMed PMID: 25252697. 2: Liebowitz MR, Tourian KA, Hwang E, Mele L; Study 3362 Investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013 Mar 22;13:94. doi: 10.1186/1471-244X-13-94. PubMed PMID: 23517291; PubMed Central PMCID: PMC3763843. 3: Khan A, Musgnung J, Ramey T, Messig M, Buckley G, Ninan PT. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol. 2014 Jun;34(3):365-8. doi: 10.1097/JCP.0000000000000100. PubMed PMID: 24717247. 4: Kornstein SG, Guico-Pabia CJ, Fayyad RS. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies. Hum Psychopharmacol. 2014 Sep;29(5):492-501. doi: 10.1002/hup.2427. Epub 2014 Aug 11. PubMed PMID: 25196042. 5: Dai F, Lei Y, Li S, Song G, Chen JD. Desvenlafaxine succinate ameliorates visceral hypersensitivity but delays solid gastric emptying in rats. Am J Physiol Gastrointest Liver Physiol. 2013 Aug 15;305(4):G333-9. doi: 10.1152/ajpgi.00224.2012. Epub 2013 Jun 13. PubMed PMID: 23764892. 6: Zong Y, Li J, Sun W, Liu G, Lu J, Shan G. [Determination of succinic acid in desvenlafaxine succinate by high performance ion-exclusion chromatography and high performance ion-exchange chromatography]. Se Pu. 2016 Feb;34(2):189-93. Chinese. PubMed PMID: 27382725. 7: Laoutidis ZG, Kioulos KT. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry. 2015 Sep;48(6):187-99. doi: 10.1055/s-0035-1555879. Epub 2015 Jul 23. Review. PubMed PMID: 26205685. 8: Berhan Y, Berhan A. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies. Ethiop J Health Sci. 2014 Jul;24(3):209-18. Review. PubMed PMID: 25183927; PubMed Central PMCID: PMC4141224. 9: Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr. 2012 Sep;17(3):121-30. doi: 10.1017/S1092852912000508. Epub 2012 Aug 10. PubMed PMID: 22883315. 10: Pinkerton JV, Archer DF, Guico-Pabia CJ, Hwang E, Cheng RF. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause. 2013 Jan;20(1):38-46. doi: 10.1097/GME.0b013e318274699f. PubMed PMID: 23266839. 11: Maity N, Ghosal MK, Gupta A, Sil A, Chakraborty S, Chatterjee S. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol. 2014 Jul-Aug;46(4):433-7. doi: 10.4103/0253-7613.135959. PubMed PMID: 25097285; PubMed Central PMCID: PMC4118540. 12: Nichols AI, Abell M, Chen Y, Behrle JA, Frick G, Paul J. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol. 2013 Mar;28(2):99-105. doi: 10.1097/YIC.0b013e32835c1f49. Erratum in: Int Clin Psychopharmacol. 2013 Jul;28(4):217. Madelyn, Abell [corrected to Abell, Madelyn]. PubMed PMID: 23221858. 13: Iwata N, Tourian KA, Hwang E, Mele L, Vialet C. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013 Jan;19(1):5-14. doi: 10.1097/01.pra.0000426323.59698.64. PubMed PMID: 23334675. 14: Cheng RJ, Dupont C, Archer DF, Bao W, Racketa J, Constantine G, Pickar JH. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric. 2013 Feb;16(1):17-27. doi: 10.3109/13697137.2012.672495. Epub 2012 May 31. PubMed PMID: 22646219. 15: Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial. J Clin Psychiatry. 2013 Feb;74(2):158-66. doi: 10.4088/JCP.12m07974. PubMed PMID: 23473348. 16: Findling RL, Groark J, Chiles D, Ramaker S, Yang L, Tourian KA. Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014 May;24(4):201-9. doi: 10.1089/cap.2012.0126. Epub 2014 Mar 10. PubMed PMID: 24611442; PubMed Central PMCID: PMC4026302. 17: Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2013 Nov;28(6):312-21. doi: 10.1097/YIC.0b013e3283638fbd. PubMed PMID: 23881185. 18: Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest. 2013;75(4):255-62. doi: 10.1159/000348564. Epub 2013 Mar 20. PubMed PMID: 23548358. 19: Carrasco JL, Kornstein SG, McIntyre RS, Fayyad R, Prieto R, Salas M, Mackell J, Boucher M. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2016 May;31(3):134-46. doi: 10.1097/YIC.0000000000000121. PubMed PMID: 26895080. 20: Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, Constantine G. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012 Feb;15(1):12-20. doi: 10.3109/13697137.2011.586445. Epub 2011 Nov 8. PubMed PMID: 22066790.